Intended for in vitro diagnostic (IVD) use. The transcription factor erythroblastosis virus E26 transforming sequence related gene (ERG) functions as a regulator of key cellular functions to promote endothelial homeostasis. Expression of ERG has been observed in both benign and malignant vascular endothelial tumors, such as hemangiomas and Kaposi sarcomas. Carcinomas of the breast, colon, and urothelium have demonstrated absence of ERG expression, whereas presence of the protein has been confirmed in a subset of prostate carcinoma cases. Anti-ERG can be a useful tool for identifying vascular endothelial neoplasms and distinguishing prostate carcinoma from epithelial tumors of non-prostatic origin.

References

1. Shah AV, et al. Regulation of endothelial homeostasis, vascular development and angiogenesis by the transcription factor ERG. Vascul Pharmacol. 2016; 86:3-13
2. Miettinen M, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol. 2011; 35:432-41.
3. Hornick JL. Novel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumors. Mod Pathol. 2014; 27:S47-S63.
4. Yaskiv O, et al. ERG protein expression in human tumors detected with a rabbit monoclonal antibody. Am J Clin Pathol. 2012; 138:803-10.

5. Minner S, et al. Marked heterogeneity of ERG expression in large primary prostate cancers. Mod Pathol. 2013; 26:106-16.